Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 July 2024
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (IPG786)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 March 2025
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC